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Domenico Galetta22
BACKGROUND: The present study investigated the efﬁcacy and safety of nivolumab in pre-treated patients with advanced NSCLC
harbouring KRAS mutations.
METHODS: Clinical data and KRAS mutational status were analysed in patients treated with nivolumab within the Italian Expanded
Access Program. Objective response rate, progression-free survival and overall survival were evaluated. Patients were monitored for
adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events.
RESULTS: Among 530 patients evaluated for KRAS mutations, 206 (39%) were positive while 324 (61%) were KRAS wild-type
mutations. KRAS status did not inﬂuence nivolumab efﬁcacy in terms of ORR (20% vs 17%, P= 0.39) and DCR (47% vs 41%, P= 0.23).
The median PFS and OS were 4 vs 3 months (P= 0.5) and 11.2 vs 10 months (P= 0.8) in the KRAS-positive vs the KRAS-negative
group. The 3-months PFS rate was signiﬁcantly higher in the KRAS-positive group as compared to the KRAS-negative group (53% vs
42%, P= 0.01). The percentage of any grade and grade 3–4 AEs were 45% vs 33% (P= 0.003) and 11% vs 6% (P= 0.03) in KRAS-
positive and KRAS-negative groups, respectively.
CONCLUSIONS: Nivolumab is an effective and safe treatment option for patients with previously treated, advanced non-squamous
NSCLC regardless of KRAS mutations.
British Journal of Cancer (2019) 120:57–62; https://doi.org/10.1038/s41416-018-0234-3
BACKGROUND
The advent of immune-checkpoint inhibitors (ICIs) in clinical
practice1 is leading to a signiﬁcant improvement of life expectancy
in patients with advanced non-small-cell lung cancer (NSCLC).
Modulating the antitumour immune response by targeting the
programmed cell death 1 (PD-1)/programmed cell death 1 ligand
(PD-L1) axis emerged as an effective and tolerable treatment in
early phase I studies,2 offering the potential for durable disease
control and long-term survival outcomes in heavily pre-treated
NSCLC patients.3 Four randomised phase III trials have subse-
quently demonstrated that single-agent ICIs, nivolumab,4,5 pem-
brolizumab6 or atezolizumab7 signiﬁcantly improved overall
survival (OS) and quality of life (QoL) as compared to docetaxel
in pre-treated NSCLC patients, emerging as new standard of care
in second or later lines of therapy. In particular, the phase III
Checkmate 057 trial5 ﬁrst demonstrated a signiﬁcant superiority in
terms of objective response rate (ORR), OS, tolerability and QoL in
favour of the anti-PD-1 nivolumab over docetaxel in pre-treated
patients with non-squamous NSCLC. Importantly, nivolumab
resulted superior to docetaxel irrespective of tumour PD-L1
expression, even if higher efﬁcacy was detected among patients
expressing high PD-L1 levels. Landmark survival analysis8 exclud-
ing patients with poor prognosis who died within the ﬁrst
3 months of therapy, has subsequently demonstrated that
patients with low or no tumour PD-L1 expression who were alive
at 3 months also beneﬁted from nivolumab. These evidences led
to the ﬁnal approval of nivolumab by regulatory authorities in
March 2016 for the second/third-line treatment of non-squamous
NSCLC regardless of tumour PD-L1 expression.9 The data
emerging from both randomised trials6,7,10 and real-life experi-
ences11,12 suggested that immunotherapy is effective in a
signiﬁcant subgroup of patients, leading to durable disease
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control, long-term survival and improved QoL. Conversely, about
50% of pre-treated patients did not gain any beneﬁt from ICIs and
a small subgroup of them developed early progression or death
within 3 months of therapy.8,11–15 Thus, identifying predictive
biomarkers of clinical response/resistance to ICIs is crucial for the
selection of an appropriate candidate to immunotherapy. Looking
for molecular predictors of ICI efﬁcacy, the pre-speciﬁed subgroup
analysis of the 057 trial10 clearly showed that nivolumab did not
improve neither PFS nor OS in patients with epidermal growth
factor receptor (EGFR)-positive NSCLC. Similar results were
obtained in trials with pembrolizumab or atezolizumab as well
as in recent meta-analysis.16,17
KRAS mutations represent the most common oncogene driver
detected in about 30% of non-squamous NSCLC, usually occurring
at codons 12–13 and associated with cigarette smoking.18,19
Several efforts have been made by the scientiﬁc community to
understand the potential role of KRAS mutations as a therapeutic
target in cancer cells, but no effective KRAS-inhibitors have been
approved yet for clinical use. The efﬁcacy of nivolumab in KRAS-
mutated NSCLC is not well deﬁned. The results from clinical trials
suggested that patients harbouring KRAS-mutations could result in
more sensitivity to nivolumab as compared to KRAS wild-type
mutations, but the small number of patients evaluated in single
trials7,10 precluded any deﬁnitive conclusion. A recent meta-
analysis17 investigated the predictive role of KRAS-mutations in
519 patients with previously treated NSCLC included in trials with
nivolumab or atezolizumab (CheckMate 057, OAK and POPLAR
studies). The results of such analysis showed a greater beneﬁt in
KRAS-mutant subgroups even if the difference was not statistically
signiﬁcant, likely because KRAS-mutation status was known only in
a small fraction of cases. In the present study, we investigated
whether nivolumab could result effective in terms of ORR, PFS and
OS in pre-treated metastatic NSCLC patients harbouring KRAS
mutations.
METHODS
Patients
The study was conducted in patients participating in the Italian
expanded access program (EAP). Patients were eligible if they
aged ≥18 years, had histologically or cytologically conﬁrmed
diagnosis of non-squamous NSCLC, stage IIIB–C/IV (according to
Version 8 of the International Association for the Study of Lung
Cancer (IASLC) TNM Staging System), Eastern Cooperative
Oncology Group (ECOG) performance-status score <3, and had
disease progression or recurrence after receiving at least one prior
systemic therapy for advanced/metastatic disease.
Patients were excluded if they had autoimmune disease,
symptomatic interstitial lung disease, systemic immunosuppres-
sion and prior treatment with immune-stimulatory antitumour
agents including checkpoint-inhibitors. Patients with brain metas-
tases were eligible if they have received prior loco-regional
treatment and were stable at the time of inclusion. Tumour PD-L1
status was not required.
The study was conducted in accordance with the International
Conference on Harmonization Guidelines on Good Clinical
Practice and the Declaration of Helsinki. The trial protocol was
previously approved by the Independent Ethics Committee and all
the patients provided a written informed consent before
enrolment.
Study design and treatment
We retrospectively collected clinical data and KRAS mutational
status from patients’ charts and hospital electronic medical
records for eligible patients who have been treated with
nivolumab at 168 Italian cancer centres from May 2015 to
December 2016. All included patients were followed until the end
of data collection on September 2017.
Nivolumab was available upon physicians’ request for eligible
patients through the EAP. Nivolumab 3mg/kg was administered
intravenously every 2 weeks for ≤24 months. Patients included in
the analysis received ≥1 dose of nivolumab. The treatment was
continued until disease progression or unacceptable toxicity, or
the completion of permitted cycles (≤24 months).
KRAS mutation testing data from tumour samples obtained
before enrolment in the EAP were used where available. DNA
extracted from tissue/cytological samples was subjected to KRAS
mutational analysis using local practices.
Radiological evaluation of treatment efﬁcacy by CT-scan was
performed at week 12 and every 12 weeks thereafter until disease
progression and responses were evaluated by Response Evalua-
tion Criteria in Solid Tumours (RECIST) v1.1. Patients were
monitored for AEs using the National Cancer Institute Common
Terminology Criteria for Adverse Events v4.0.
Statistical analysis
The main objective of the study was to assess nivolumab efﬁcacy
in terms of ORR, PFS and OS in NSCLC patients with or without
KRAS mutations. Secondary endpoint was to assess whether
nivolumab safety proﬁle was different in individuals with or
without KRAS mutations.
For efﬁcacy analysis, patients were grouped according to their
tumour KRAS mutational status into ‘positive’ if they harboured
KRAS mutations or ‘negative’ if they did not have KRAS mutations.
Patients’ clinical–pathological characteristics and associations with
KRAS mutational status were examined with a descriptive analysis
comparing the differences by χ2 test or Fisher’s exact test as
appropriate.
Investigator-assessed efﬁcacy outcomes, including ORR, disease
control rate (DCR), median PFS and OS, were assessed in KRAS-
positive vs KRAS-negative patients both in the overall population
and in predeﬁned subgroups of patients. ORR was deﬁned as the
combined rates of complete response (CR) and partial response
(PR). DCR was deﬁned as the combined rates of CR, PR and stable
disease (SD). Median PFS was deﬁned as the time between the
date of inclusion and the date of disease progression determined
by RECIST v1.1, death from any cause or the last follow-up. Median
OS was deﬁned as the time between the date of inclusion and the
date of death. Survival analysis was performed using Kaplan–Meier
method, providing median and P-values, with the use of the log-
rank test for comparisons. Univariate and multivariate analyses
were performed using the logistic regression model when
referring to binary outcome and Cox regression model when
considering time to events. A P-value < 0.05 was used as a
threshold for statistical signiﬁcance.
All statistical analyses were performed with SPSS Statistics
software version 21 (IBM, Armonk, New York, USA).
RESULTS
Patients’ characteristics
From May 2015 to December 2016, a total of 1588 non-squamous
NSCLC patients were considered eligible and participated in the
EAP at 168 centres in Italy. Among 530 patients evaluated for KRAS
mutations, 206 (39%) resulted positive while 324 (61%) were KRAS
wild-type mutations. KRAS mutation subtypes were not known in
the analysed population. Epidermal growth factor receptor (EGFR)-
activating mutations were detected in 17/324 patients (5%), while
ALK/ROS1 rearrangements were found in 7/324 (2%) of KRAS wild-
type patients. As reported in Table 1, the baseline characteristics
were similar between the two subgroups. However, in the KRAS-
positive group, the percentage of current/former smokers was
signiﬁcantly higher than in the KRAS-negative group (86% vs 76%,
P= 0.01), as was the percentage of patients with CNS metastasis
(29% vs 20%, P= 0.01). Patients with KRAS mutations received a
median of eight doses (range: 1–54), with a median follow-up of
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8.0 months (range: 0.1–25.9), while KRAS-negative patients
received a median of seven doses (range: 1–52), with a median
follow-up of 7.4 months (range: 0.2–27.4).
KRAS mutations and tumour response
Among patients with KRAS-positive NSCLC treated with nivolu-
mab, one patient (0.5%) experienced CR, 39 (19%) had a partial
response (PR), 55 (27%) stable disease (SD) and 88 (43%)
progressive disease (PD). No signiﬁcant differences between
KRAS-positive and KRAS-negative patients have been observed
as regards both ORR (20% vs 17%, P= 0.39) and DCR (47% vs 41%,
P= 0.23), as illustrated in Table 2. The results of both ORR and DCR
analyses across different predeﬁned subgroups of patients were
consistent with those observed in the overall population.
KRAS mutations and patients’ survival
As illustrated in Fig. 1, at the time of survival analysis (median
follow-up of 8.1 months, range: 0.1–27.4), median PFS was
4 months (95% CI: 3.6, 4.4) in the KRAS-positive group and
3 months (95% CI: 3.6–4.4) in the KRAS-negative group (P= 0.56).
The 3-months PFS rate was signiﬁcantly higher in the KRAS-positive
group as compared to the KRAS-negative group (53% vs 42%,
P= 0.01). The 6-months and 12-months PFS rate was similar
between the two groups. The 6-months rate of PFS was 33%
in the KRAS-positive group and 31% in the KRAS-negative group
(P= 0.63); the 12-months rate of PFS was 19% in both the groups
(P= 0.99).
There were no signiﬁcant OS differences between KRAS-positive
and KRAS-negative patients. The median OS was 11.2 months
(95% CI: 9.3–13.1) in the KRAS-positive group and 10 months
(95% CI: 9.3–13.1) in the KRAS-negative group (P= 0.86, Fig. 2).
Table 1. Baseline patients’ characteristics
Characteristic KRAS-positive
(n= 206)
KRAS-negative
(n= 324)
P-value
Median age, years
(range)
66 (36–87) 65 (29–86) 0.09
Male, n (%) 129 (63) 218 (67) 0.27
Smoking status, n (%) 0.01
Smoker 45 (24) 78 (25)
Former smoker 119 (62) 157 (51)
Never-smoker 27 (14) 75 (24)
Unknown 15 14
ECOG PS, n (%)
0 80 (39) 132 (41) 0.88
1 111 (54) 167 (52)
2 14 (7) 21 (7)
Unknown 1 4
Metastatic site, n (%)
CNS 60 (29) 64 (20) 0.01
Liver 35 (17) 77 (24) 0.06
Number of prior
therapies, n (%)
1 89 (43) 125 (39) 0.49
2 52 (25) 97 (30)
3 41 (20) 57 (18)
≥4 24 (14) 44 (14)
n number of patients, PS performance status, CNS central nervous system.
Bold values indicate statistical signiﬁcance
Table 2. Response to treatment
Response, n (%) KRAS-positive
(n= 206)
KRAS-negative
(n= 324)
P-value
ORR 41 (20) 55 (17) 0.39
DCR 96 (47) 134 (41) 0.23
Best overall response
CR 2 (1) 1 (<1)
PR 39 (19) 54 (17)
SD 55 (27) 79 (24)
PD 88 (43) 153 (47)
Death 12 (5) 30 (9)
Not determined 10 (5) 7 (2)
n number of patients, ORR objective response rate, DCR disease control
rate, CR complete response, PR partial response, SD stable disease, PD
progression disease
1.0 Median PFS: 4 months vs 3 months; p = 0.56
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Fig. 1 Kaplan–Meier analysis of progression-free survival (PFS) in
NSCLC patients according to the KRAS-mutation status
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Fig. 2 Kaplan–Meier analysis of overall survival (OS) in NSCLC
patients according to the KRAS-mutation status
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The 3-months rate of OS was 84% in the KRAS-positive group and
78% in the KRAS-negative group (P= 0.09); the 6-months rate
of OS was 71% in the KRAS-positive group and 64% in the
KRAS-negative group (P= 0.09); the 12-months rate of OS was
47% in the KRAS-positive group and 46% in the KRAS-negative
group (P= 0.92). The results of ORR, PFS and OS analyses across
different predeﬁned subgroups of patients were consistent with
those observed in the overall population.
Safety
Treatment-related AEs (TRAEs) of any grade and grade 3–4 for
KRAS-positive and KRAS-negative non-squamous NSCLC patients
treated with nivolumab are shown in Table 3. The percentage of
patients with TRAEs of any grade was signiﬁcantly higher in the
KRAS-positive group (45% vs 33%, P= 0.003) as was the
percentage of patients with TRAEs of grade 3–4 (11% vs 6%,
P= 0.03). The percentage of patients who discontinued treatment
was 81% in KRAS-positive and 84% in KRAS-negative patients.
TRAEs leading to discontinuation were hepatic, gastrointestinal
and pulmonary with similar frequencies observed in the different
subgroups of patients. No treatment-related deaths have been
reported. The results of safety analyses across different predeﬁned
subgroups of patients were consistent with those observed in the
overall population.
Multivariable analysis
Multivariable Cox proportional regression analysis was performed
to assess whether KRAS mutations were independent factors
related to nivolumab safety in terms of any grade and grade 3–4
toxicities. All clinical–pathological parameters found to have a
P-value < 0.05 at univariate analysis were included as covariates in
the multivariable model.
KRAS mutations remained signiﬁcantly associated with higher
toxicity rate, including both any grade AEs (OR: 1.66 (1.14–2.41)
P= 0.008) and grade 3–4 AEs (OR: 2.25 (1.14–4.44) P= 0.02)
(Table 4).
DISCUSSION
To the best of our knowledge, this is the largest study
investigating the predictive role of KRAS mutations in advanced
non-squamous NSCLC treated with nivolumab. The results of this
real-world analysis demonstrated that both clinical efﬁcacy and
safety of nivolumab were comparable to those observed in the
phase III randomised CheckMate 057 trial, including the same
NSCLC population.5
Our results demonstrated that KRAS status is not a reliable
predictor of nivolumab efﬁcacy in terms of RR, PFS and OS.
Differences in all clinical endpoints were not statistically
Table 3. Treatment-related adverse events (TRAEs)
Event KRAS-positive
(n= 206)
KRAS-negative
(n= 324)
Any
grade,
n (%)
Grade
3–4,
n (%)
Any
grade,
n (%)
Grade
3–4,
n (%)
Any treatment-related
AE
93 (45) 22 (11) 108 (33) 18 (6)
General
Fatigue/asthenia 39 (19) 9 (4) 34 (10) 8 (2)
Pyrexia 12 (6) 0 11 (3) 0
Anorexia 11 (5) 1 (<1) 18 (6) 0
Skin and mucosal 16 (8) 1 (<1) 22 (7) 3 (1)
Rash 2 (1) 0 9 (3) 1 (<1)
Gastrointestinal 35 (17) 4 (2) 41 (13) 4 (2)
Diarrhoea 8 (4) 1 (<1) 16 (5) 1 (<1)
Nausea/vomiting 11 (5) 1 (<1) 12 (4) 1 (<1)
Haematologic 12 (6) 2 (1) 6 (2) 3 (1)
Anaemia 6 (3) 2 (1) 5 (2) 3 (1)
Pain 19 (9) 2 (<1) 19 (6) 1 (<1)
Hepatic/pancreatic 14 (7) 43 (2) 15 (5) 2 (1)
Increased
transaminase
7 (3) 2 (1) 3 (1) 0
Increased lipase/
amylase
1 (<1) 0 2 (1) 0
Endocrine 10 (5) 1 (<1) 18 (6) 1 (<1)
Hypothyroidism 5 (2) 1 (<1) 9 (3) 0
Hyperthyroidism 5 (2) 0 7 (2) 0
Autoimmune
hypophysitis
0 0 0 0
Respiratory/
pulmonary
36 (17) 4 (2) 43 (13) 6 (2)
Dyspnoea 13 (6) 3 (1) 18 (6) 2 (1)
Pneumonitis 6 (3) 1 (<1) 8 (2) 3 (1)
n number of patients, AE adverse event, TRAEs treatment-related adverse
events
Table 4. Univariable and multivariable analysis
Parameter Any grade TrAEs G3–4 TrAEs
Univariable OR (95% CI); P Multivariable OR (95% CI); P Univariable OR (95% CI); P Multivariable OR (95% CI); P
KRAS status(mut vs wt) 0.57 (0.35–0.91)P= 0.02 1.66 (1.14–2.41)P= 0.008 0.74 (0.30–1.83)P= 0.52 2.03 (1.06–3.89)P= 0.03
Age (years) 0.99 (0.97–1.01)P= 0.17 — 0.97 (0.94–1.01)P= 0.10 —
Sex 0.82 (0.57–1.18)P= 0.29 — 0.98 (0.50–1.92)P= 0.95 —
ECOG PS(2 vs 0–1) 0.74 (0.35–1.54)P= 0.41 — 0.73 (0.17–3.16)P= 0.67 —
Smoking habits(never vs current/
former)
1.65 (1.15–2.36)P= 0.006 0.59 (0.36–0.95)P= 0.03 2.03 (1.06–3.89)P= 0.03 —
Brain metastasis (yes vs no) 1.24 (0.82–1.87)P= 0.30 — 1.44 (0.71–2.93)P= 0.31 —
Liver metastasis (yes vs no) 0.62 (0.40–0.98)P= 0.04 — 0.78 (0.33–1.81)P= 0.56 —
Previous lines (>1 vs 1) 0.82 (0.57–1.17)P= 0.27 — 0.82 (0.43–1.56)P= 0.54 —
n number of patients, TRAEs treatment-related adverse events, OR odds ratio, 95% CI conﬁdence intervals, P P-value, PS performance status, mut mutated, wt
wild-type
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signiﬁcant, with the only exception of 3-months PFS that was
signiﬁcantly higher in the KRAS-positive group.
Interest in KRAS mutant NSCLC is growing because of the lack of
any speciﬁc agent available in patients harbouring such molecular
alteration, the high incidence in non-squamous NSCLC and the
association with smoking history and therefore with tumour
mutational burden, one of the most innovative predictive
biomarkers to immunotherapy. Preclinical and clinical evidences
suggested that KRAS-positive NSCLC seems to gain more beneﬁt
from immunotherapy. First of all, KRAS-mutant tumours are
characterised by the presence of CD8+ lymphocyte inﬁltrates in
the tumour microenvironment (TME),20 while a signiﬁcant
association between KRAS mutations and PD-L1 expression has
been observed in lung adenocarcinoma.21,22 Coelho et al.23 have
recently demonstrated that oncogenic RAS signalling upregulated
tumour PD-L1 expression stabilising the PD-L1 transcript in KRAS-
mutant adenocarcinoma, thus providing an additional mechanism
whereby KRAS-positive tumours respond to PD-1/PD-L1 inhibitors.
Recent studies demonstrated how the crosstalk between the
cancer cells intrinsic RAS signalling and the TME extended beyond
the tumour PD-L1 expression, regulating many other different TME
components,24 such as inﬂammatory cells, immune T-cells and
myeloid cells density, cancer-associated ﬁbroblasts and endothe-
lial cells properties and extracellular matrix (ECM) composition,
ultimately favouring immune-escape, cancer growth and meta-
static process. The possibility of using KRAS status for selecting
patients potentially sensitive to immunotherapy is certainly of
great interest. Indeed, this biomarker is generally included among
the molecular tests performed in metastatic NSCLC, facilities are
available in the majority of centres, it is relatively easy to perform
and not expansive. However, it is now clear that KRAS-mutant
NSCLC is a heterogeneous disease, including different tumour
subtypes with variable biological background, different prognosis
and clinical response to immunotherapy. A recent work25 showed
that tumours with co-occurring KRAS/P53 mutations were asso-
ciated with higher PD-L1 expression as well as elevated PD-L1
+/CD8+ cell ratio and increased mutation burden as compared to
tumours with KRAS or P53 single mutation. Interestingly, patients
with KRAS+/P53+ NSCLC also showed a remarkable and durable
clinical beneﬁt from anti-PD-1 therapy, suggesting a synergistic
and complementary effect of both signalling pathways to the
TME immunogenicity. Conversely co-occurring inactivation of
LKB1/STK11 tumour suppressor gene was associated with lack
of tumour response and shorter PFS and OS as compared to
LKB1/STK11 wild-type patients with KRAS-mutant lung adenocarci-
noma, suggesting LKB1-loss as a major driver of immune-escape
and a genomic biomarker of innate resistance to ICIs.26 Previous
reports described as the inactivation of LKB1 were associated with
lower PD-L1 expression levels and paucity of inﬁltrating CD8+
lymphocytes in the TME of KRAS-positive NSCLC,27 suggesting that
normal LKB1 tumour suppressor gene plays a crucial role in
maintaining a KRAS-mutant-driven immunosuppressive TME.
Recent ﬁndings demonstrated that STK11/LKB1 alterations are
associated with lack of response to PD-1 inhibitors efﬁcacy,
regardless of KRAS mutations or PD-L1 expression status,26,28
suggesting that different combinations of P53, STK11 and EGFR
mutations were associated with different tumour microenviron-
ments and may predict clinical response to PD-1 blockade.28
Unfortunately, neither P53 nor LKB1 status were known for KRAS-
positive NSCLC patients included in our study because of the lack
of tumour tissue available for molecular analysis. Since only 24/324
KRAS wild-type patients had EGFR-activating mutations or
ALK/ROS1 rearrangements, we were not able to evaluate their
impact on efﬁcacy outcomes observed with nivolumab in the
overall population. Further trials including larger cohorts of NSCLC
patients with known KRAS, P53, STK11, EGFR and PD-L1 status are
warranted.
Interestingly, our series provided new information with
regard to nivolumab tolerability according to tumour KRAS-
mutation status in a real-life setting. Although nivolumab was
overall well tolerated, the percentage of both any grade and
grade 3–4 TRAEs was signiﬁcantly higher in the KRAS-positive
group, suggesting a potential interaction between KRAS-
signalling and treatment tolerability. The reasons for this
observation remain speculative and warrant further investiga-
tion in clinical studies. However, imbalances in the clinical
characteristics of patients at baseline may have inﬂuenced the
different tolerability proﬁle of nivolumab between the two
treatment groups.
In conclusion, the results of this study showed that KRAS
mutations are not useful for selecting patients candidate to
nivolumab therapy. Nivolumab is an effective and safe treatment
option for patients with previously treated, advanced NSCLC
regardless of KRAS-mutation status.
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